Cristina Cusin, MD is the Founder and Director of the MGH Ketamine Clinic, a psychiatrist in the Depression Clinical and Research Program, and an Associate Professor in Psychiatry at Harvard Medical School. Her research and clinical work has focused on the treatment of treatment-refractory mood disorders, using innovative strategies including ketamine and deep brain stimulation.
-
Like ketamine, xenon modulates glutaminergic neurotransmission and is an antagonist of the NMDA receptor. Does it also have antidepressant effects? -
In adults with moderate to severe depression, heated yoga sessions delivered over an 8 week period were associated with clinically significant reductions in depressive symptoms. -
Benzodiazepine use did not impact treatment response; however, in patients on higher benzodiazepine dosage, ketamine may be less effective at first. -
Artificial intelligence may be able to use data from wearable devices and smartphones to improve mental health care by providing real-time updates to clinicians. -
Can ketamine be used to decrease suicidality and risk of suicide after discharge from psychiatric hospitalization? -
New research focuses on improving strategies for predicting risk of suicide, advancing our understanding of suicide risk in unique populations, and designing interventions to reduce […]